Hypoglycemia is common and potentially dangerous among those treated for diabetes. Electronic health records (EHRs) are important resources for hypoglycemia surveillance. In this study, we report the development and evaluation of deep learning-based natural language processing systems to automatically detect hypoglycemia events from the EHR narratives. Experts in Public Health annotated 500 EHR notes from patients with diabetes. We used this annotated dataset to train and evaluate HYPE, supervised NLP systems for hypoglycemia detection. In our experiment, the convolutional neural network model yielded promising performance $Precision=0.96 \pm 0.03, Recall=0.86 \pm 0.03, F1=0.91 \pm 0.03$ in a 10-fold cross-validation setting. Despite the annotated data is highly imbalanced, our CNN-based HYPE system still achieved a high performance for hypoglycemia detection. HYPE could be used for EHR-based hypoglycemia surveillance and to facilitate clinicians for timely treatment of high-risk patients.
A deep learning algorithm can detect metastases in sections of lymph nodes from women with breast cancer; and a deep learning system (DLS) has high sensitivity and specificity for identifying diabetic retinopathy, according to two studies published online Dec. 12 in the Journal of the American Medical Association.
A deep learning algorithm can detect metastases in sections of lymph nodes from women with breast cancer; and a deep learning system (DLS) has high sensitivity and specificity for identifying diabetic retinopathy, according to two studies published online December 12 in the Journal of the American Medical Association.
Varadarajan, Avinash, Bavishi, Pinal, Raumviboonsuk, Paisan, Chotcomwongse, Peranut, Venugopalan, Subhashini, Narayanaswamy, Arunachalam, Cuadros, Jorge, Kanai, Kuniyoshi, Bresnick, George, Tadarati, Mongkol, Silpa-archa, Sukhum, Limwattanayingyong, Jirawut, Nganthavee, Variya, Ledsam, Joe, Keane, Pearse A, Corrado, Greg S, Peng, Lily, Webster, Dale R
Diabetic eye disease is one of the fastest growing causes of preventable blindness. With the advent of anti-VEGF (vascular endothelial growth factor) therapies, it has become increasingly important to detect center-involved diabetic macular edema. However, center-involved diabetic macular edema is diagnosed using optical coherence tomography (OCT), which is not generally available at screening sites because of cost and workflow constraints. Instead, screening programs rely on the detection of hard exudates as a proxy for DME on color fundus photographs, often resulting in high false positive or false negative calls. To improve the accuracy of DME screening, we trained a deep learning model to use color fundus photographs to predict DME grades derived from OCT exams. Our "OCT-DME" model had an AUC of 0.89 (95% CI: 0.87-0.91), which corresponds to a sensitivity of 85% at a specificity of 80%. In comparison, three retinal specialists had similar sensitivities (82-85%), but only half the specificity (45-50%, p<0.001 for each comparison with model). The positive predictive value (PPV) of the OCT-DME model was 61% (95% CI: 56-66%), approximately double the 36-38% by the retina specialists. In addition, we used saliency and other techniques to examine how the model is making its prediction. The ability of deep learning algorithms to make clinically relevant predictions that generally require sophisticated 3D-imaging equipment from simple 2D images has broad relevance to many other applications in medical imaging.
A new study conducted by researchers from Genentech and Roche shows first-time proof that artificial intelligence can detect the severity of diabetic macular edema, which is a leading cause of blindness. On Monday, researchers from Genentech and its parent company Roche published the study, Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs" in the journal, Investigative Ophthalmology & Visual Science. The study showed that artificial intelligence can be used to provide widespread, cost-effective eye screenings via telemedicine to assist ophthalmologists in improving vision outcomes for millions of people with diabetes who may not be getting regular eye exams. The article is the first to be published that is part of a Roche/Genentech's Ophthalmology Personalized Healthcare initiative. The initiative, Roche said in a statement, aims to combine meaningful large-scale data and AI technology to predict and prevent ocular conditions and ...